12:00 AM
 | 
Oct 04, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Neuprex (rBPI-21): Discontinued Phase III trial

The company also is analyzing data from its completed Phase III trial of Neuprex to treat meningococcemia, which it plans to review with the FDA (see BioCentury, Aug. 23).

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >